FRA, ER4 End of Day and Historical Stock Data []

The worlds #1 website for end of day & historical stock data

wide range of exchanges, data formats, tools and services

APINEW HISTORICAL DATA SYMBOL LISTS MEMBERSHIP REGISTER LOG IN

FRA, ER4: Emergent BioSolutions Inc

04 Sep 2025

LAST: 6.656	CHANGE: 0.34	OPEN: 6.656	HIGH: 6.656	ASK: 0.000	VOLUME: 80
LAST: 6.656	CHG(%): 4.86	PREV: 6.996	LOW: 6.656	BID: 0.000

CHART

Period:

RECENT END OF DAY PRICES

Date	Open	High	Low	Close	Volume
04 Sep 25	6.656	6.656	6.656	6.656	80
03 Sep 25	6.996	6.996	6.996	6.996	80
02 Sep 25	7.008	7.008	7.008	7.008	80
01 Sep 25	6.984	6.984	6.984	6.984	80
29 Aug 25	7.092	7.092	7.092	7.092	80
28 Aug 25	7.290	7.290	7.290	7.290	80
27 Aug 25	7.400	7.400	7.400	7.400	80
26 Aug 25	7.824	7.824	7.824	7.824	80
25 Aug 25	7.810	7.810	7.792	7.792	80
22 Aug 25	7.950	7.950	7.950	7.950	2.1K

COMPANY PROFILE

Name:	Emergent BioSolutions Inc
About:	Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Sector:	Healthcare
Address:	300 Professional Drive, Gaithersburg, MD, United States, 20879
Website:	https://www.emergentbiosolutions.com
ISIN:	US29089Q1058
LEI:	549300YW6TUOX8BE5103

SYMBOL HISTORY

Purchase End of Day History
for this symbol from Jan 01, 0001

Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

Exchange:

Format:

Period:

Zip file

Symbol:

Start Date:

End Date:

FUNDAMENTALS

P/E Ratio:	3.12
Price to Book:	0.82
Price to Sales:	0.44
EBITDA:	216.8M
Shares:	53.35M
Market Cap:	355.1M

TECHNICAL INDICATORS

MA5:	6.95
MA10:	7.30
MA20:	7.38
MA50:	6.44
MA100:	5.81
MA200:	6.76
RSI14:	30.51
WPR14:	-100.00
MTM14:	-0.84
ROC14:	-0.11
ATR:	0.14
Week High:	7.29
Week Low:	6.66
Month High:	7.98
Month Low:	4.87
Year High:	11.36
Year Low:	3.75
Volatility:	95.64